Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3022% above fair value
$465.67−1.39 (-0.30%)
Close on Nov 13, 2026Market cap $251.76BP/E 27.0Yield 2.07%
Amgen ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Amgen's ebitda for the twelve months ending Sep 30, 2026 was $15.31B, up 28.6% year over year. For fiscal 2025 it was $14.25B, up 10.9% from the year before. Over ten years it grew 3.0% a year on average. The highest annual figure on record is $14.25B in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.25B | +10.9% |
| FY2024 | Dec 31, 2024 | $12.85B | +7.4% |
| FY2023 | Dec 31, 2023 | $11.97B | -7.8% |
| FY2022 | Dec 31, 2022 | $12.98B | +17.6% |
| FY2021 | Dec 31, 2021 | $11.04B | -13.4% |
| FY2020 | Dec 31, 2020 | $12.74B | +7.2% |
| FY2019 | Dec 31, 2019 | $11.88B | -2.7% |
| FY2018 | Dec 31, 2018 | $12.21B | +2.4% |
| FY2017 | Dec 31, 2017 | $11.93B | +0.2% |
| FY2016 | Dec 31, 2016 | $11.90B | +12.5% |
| FY2015 | Dec 31, 2015 | $10.58B | +27.7% |
| FY2014 | Dec 31, 2014 | $8.28B | +15.8% |
| FY2013 | Dec 31, 2013 | $7.15B | +7.3% |
| FY2012 | Dec 31, 2012 | $6.67B | +24.1% |
| FY2011 | Dec 31, 2011 | $5.37B | -18.1% |
| FY2010 | Dec 31, 2010 | $6.56B | +0.1% |
| FY2009 | Dec 31, 2009 | $6.56B | +4.3% |
| FY2008 | Dec 31, 2008 | $6.29B | +21.3% |
| FY2007 | Dec 31, 2007 | $5.18B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.94B | +43.0% |
| Q2 FY2026 | Jun 30, 2026 | $3.74B | +29.9% |
| Q1 FY2026 | Mar 31, 2026 | $3.78B | +47.4% |
| Q4 FY2025 | Dec 31, 2025 | $3.85B | +3.9% |
| Q3 FY2025 | Sep 30, 2025 | $2.76B | +22.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.88B | +36.2% |
| Q1 FY2025 | Mar 31, 2025 | $2.57B | +7.3% |
| Q4 FY2024 | Dec 31, 2024 | $3.71B | +39.9% |
| Q3 FY2024 | Sep 30, 2024 | $2.25B | -23.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.11B | -41.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.39B | -15.3% |
| Q4 FY2023 | Dec 31, 2023 | $2.65B | -15.6% |
| Q3 FY2023 | Sep 30, 2023 | $2.92B | -16.6% |
| Q2 FY2023 | Jun 30, 2023 | $3.58B | +19.2% |
| Q1 FY2023 | Mar 31, 2023 | $2.82B | -15.6% |
| Q4 FY2022 | Dec 31, 2022 | $3.14B | -0.5% |
| Q3 FY2022 | Sep 30, 2022 | $3.50B | +17.7% |
| Q2 FY2022 | Jun 30, 2022 | $3.00B | +4.3% |
| Q1 FY2022 | Mar 31, 2022 | $3.34B | -0.4% |
| Q4 FY2021 | Dec 31, 2021 | $3.16B | -3.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.97B | -8.7% |
| Q4 FY2020 | Dec 31, 2020 | $2.88B | -9.4% |
| Q3 FY2020 | Sep 30, 2020 | $3.35B | +13.0% |
| Q2 FY2020 | Jun 30, 2020 | $3.25B | +13.3% |
| Q1 FY2020 | Mar 31, 2020 | $3.25B | +15.2% |
| Q2 FY2019 | Jun 30, 2019 | $3.18B | -4.1% |
| Q1 FY2019 | Mar 31, 2019 | $2.97B | -7.2% |
| Q4 FY2018 | Dec 31, 2018 | $2.87B | +6.6% |
| Q3 FY2018 | Sep 30, 2018 | $2.82B | -2.7% |
| Q2 FY2018 | Jun 30, 2018 | $3.32B | +3.1% |
| Q1 FY2018 | Mar 31, 2018 | $3.20B | +2.6% |
| Q4 FY2017 | Dec 31, 2017 | $2.69B | -11.5% |
| Q3 FY2017 | Sep 30, 2017 | $2.90B | -4.2% |
| Q2 FY2017 | Jun 30, 2017 | $3.22B | +10.8% |
| Q1 FY2017 | Mar 31, 2017 | $3.12B | – |
| Q4 FY2016 | Dec 31, 2016 | $3.04B | – |
| Q3 FY2016 | Sep 30, 2016 | $3.03B | – |
| Q2 FY2016 | Jun 30, 2016 | $2.90B | – |
See a number that looks wrong?